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Background: To study the expression of D2R, MGMT and VEGF for clinical significance in pituitary adenomas, and
to predict the potential curative medical therapy of dopamine agonists, temozolomide and bevacizumab on
pituitary adenomas.
Methods: Immunohistochemistry and western blot were performed to detect the expression of expression of D2R,
MGMT and VEGF in pituitary adenoma tissue samples. The ratio of high expression of D2R, MGMT or VEGF in
different subtypes of PA was compared by the use of chi-squared tests. The relationships between D2R, MGMT and
VEGF expression were assessed by the Spearman rank correlation test. The association between their expression
and clinical parameters was analyzed using a chi-squared test, or Fisher's exact probability test when appropriate.
Results: The data showed that in 197 different histological subtypes of pituitary adenomas (PAs), 64.9% of them
were D2R high expression, 86.3% were MGMT low expression and 58.9% were VEGF high expression. D2R high
expression existed more frequently in PRL- and GH- secreting PAs. MGMT low expression existed in all PA subtypes.
VEGF high expression existed more frequently in PRL, ACTH, FSH secreting and non-functioning PAs. The data of
western blot also support the results. Spearman's rank correlation analysis showed that expression of MGMT was
positively associated with D2R (r = 0.154, P = 0.031) and VEGF (r = 0.161, P = 0.024) in PAs, but no correlation was
showed between D2R and VEGF expression (r = −0.025, P = 0.725 > 0.05). The association between their expression
and clinical parameters was analyzed using a chi-squared test, or Fisher's exact probability test when appropriate,
but the result showed no significant association.
Conclusions: PRL-and GH-secreting PAs exist high expression of D2R, responding to dopamine agonists; Most PAs
exist low expression of MGMT and high expression of VEGF, TMZ or bevacizumab treatment could be applied under
the premise of indications.
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Pituitary adenomas (PAs) account for about 15% of intra-
cranial tumors. Although PAs are mostly benign lesions,
about 30-55% of them are confirmed to locally invasive,
and some of them infiltrate dura, bone and sinuses, are
designated highly aggressive [1,2]. The conventional treat-
ment of large pituitary adenomas consists of surgery, and
radiotherapy when it is hard to achieve total resection. The
use of additional radiotherapy is limited by the risk of radi-
ation necrosis of surrounding structures. Thus, medication
treatment, although unlikely to be curative immediately,
might lead to certain clinically therapeutic effect, as a use-
ful supplement [3].
Currently, first-line clinical medication for PAs gener-
ally consists of dopamine agonists (DAs), somatostatin
analogs (SSAs) or combinations [4]. Recently, some rou-
tine chemotherapeutics such as Temozolomide (TMZ)
and Bevacizumab have been carefully studied to treat
PAs and considered to be potential for aggressive PAs’
medical therapy [5-8]. DAs were widely used for the
treatment of prolactinomas and some somatotropino-
mas, and the responsiveness depends on the expression
of dopamine D2 receptors (D2R) on tumor cells. Abnor-
mal expression of D2R in prolactinoma was considered
to confer resistance to DA treatment. Fadul et al. [7] first
reported two cases of pituitary carcinoma received TMZ
treatment, concluding that TMZ may be effective in
treating pituitary carcinomas. After that, more and more
studies demonstrated the inspiring therapeutic effect of
TMZ on pituitary carcinomas and aggressive PAs. As a
DNA repairase, O6-methylguanine DNA methyltransfer-
ase (MGMT) confers chemoresistance to TMZ [9]. Thus,
tumors with low expression of MGMT are usually sensi-
tive to TMZ. Bevacizumab is a monoclonal antibody
which has been approved by USA FDA to treat colorectal
cancer, non-small-cell lung carcinoma, breast cancer, renal
carcinoma and recurrent glioma [10]. It blocks vascular
endothelial growth factor (VEGF) binding to its receptor
[11]. Experimental and clinical studies have demonstrated
that anti-VEGF therapy may be effective in pituitary car-
cinoma and aggressive PAs.
To investigate D2R, MGMT and VEGF expression
profile in PAs, and to evaluate the status of the drug tar-
gets of DAs, TMZ and Bevacizumab for PA medical
therapy, herein, we performed the immunohistochemical
staining in 197 cases of different subtypes of PAs.
Methods
Patients and tissues
One hundred and ninety seven pituitary adenomas (PAs)
of different histological subtypes were selected randomly
from patients operated between 2009 and 2011 in the
Department of neurosurgery, Jinling Hospital, School of
Medicine, Nanjing University. All PA tumor tissues wereformalin-fixed and paraffinembedded resected and then
pathologically diagnosed, including 28 PRL-secreting aden-
omas, 20 GH-secreting adenomas, 27 ACTH-secreting ad-
enomas, 15 TSH-secreting adenomas, 37 FSH-secreting
adenomas and 70 non-functioning adenomas.
Immunohistochemical staining
A streptavidin-peroxidase (SP) method was used for im-
munostaining. Briefly, slides were deparaffinized with xy-
lene three times (each for 5–10 min), dehydrated three
times in a gradient series of ethanol (100%, 95%, and 75%),
and rinsed with PBS. Each slide was treated with 3% H2O2
for 15 min to quench endogenous peroxidase activity.
Nonspecific bindings were blocked by treating slides with
normal goat serum for 20 min. Slides were first incubated
with rabbit polyclonal anti-D2R (Abcam, Shanghai, China;
1:50), mouse monoclonal anti-MGMT (Abcam, Shanghai,
China; 1:50) or mouse monoclonal anti-VEGF (Abcam,
Shanghai, China; 1:50) overnight at 4°C, and then rinsed
twice with PBS. Slides were then incubated with a second-
ary antibody for 15 min at 37°C followed by treatment with
streptavidin–peroxidase reagent for 15 min, and rinsed
twice with PBS. The slides were visualized with 3,3’-diami-
nobenzidine (DAB) for 3 min, counterstained with haema-
toxylin, and mounted for microscopy.
Evaluation of staining
The slides were evaluated by two separate investiga-
tors under a light microscope (Dr. Wanchun Li and
Dr. Zhenfeng Lu). Staining intensity was scored as 0
(negative), 1 (weak), 2 (medium), and 3 (strong). Extent of
staining was scored as 0 (0%), 1 (1–25%), 2 (26-50%), 3
(51-75%), and 4 (76-100%) according to the percentages of
the positive staining areas in relation to the whole carcin-
oma area. The sum of the intensity score and extent score
was used as the final staining score (0–7). Tumors having
a final staining score of >2 were considered to be positive,
score of 2–3 were considered as low expression and score
of >3 were high expression.
Western blot
For western blot analysis, the lysates were separated by
SDS-PAGE followed by transferring to an Immobilon-P
Transfer membrane (Millipore Corporation, Bedford, MA,
USA). Membranes were probed with primary antibodies
followed by incubation with secondary antibody. Proteins
were visualized with chemiluminescence luminol reagents
(Beyotime Institute of Biotechnology, Shanghai, China).
Statistical analysis
Statistical analysis was performed using SPSS 16.0 (SPSS
Chicago, IL, USA). The ratio of high expression of D2R,
MGMT or VEGF in different subtypes of PA was com-
pared by the use of chi-squared tests. The relationships
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by the Spearman rank correlation test. The association be-
tween their expression and clinical parameters was ana-
lyzed using a chi-squared test, or Fisher's exact probability
test when appropriate. P < 0.05 was considered to be statis-
tically significant.
Results
Expression of D2R, MGMT or VEGF in PA tissues
The location of D2R and VEGF in the nuclei and cyto-
plasm, and of MGMT in the nuclei was considered for
scoring (Figure 1A–F). The positive expression of D2R
was detected in 194 tissues, of MGMT was in all tissues
and of VEGF was in 190 tissues. The proportions of
cases showing low (score of ≤3) or high (score of >3) ex-
pression levels for D2R, MGMT and VEGF in different
subtypes of PA were shown in Table 1. 64.9% of 197 PAs
were D2R high expression, 86.3% of them were MGMT
low expression and 58.9% of them were VEGF high expres-
sion. The ratio of high expression of D2R or MGMT is sig-
nificantly different in PA subtypes (For D2R: χ2 = 44.844,
P < 0.001; For MGMT: χ2 = 13.210, P = 0.021), but for
VEGF, there is no significance (χ2 = 9.003, P = 0.109). D2RFigure 1 Expression of D2R, MGMT and VEGF in PAs. (A, B): D2R low (
(D) expression. (E, F): VEGF low (E) and high (F) expression. Bar = 50 μm.high expression existed more frequently in PRL, GH,
ACTH, TSH and FSH secreting PAs. MGMT low ex-
pression existed in all PA subtypes. VEGF high expression
existed more frequently in PRL, ACTH, FSH secreting and
non-functioning PA. The data of western blot supported
and confirmed these results (Figure 2).
Relationships between D2R, MGMT and VEGF expression
in correlation analysis
Spearman's rank correlation analysis showed that MGMT
expression was positively associated with D2R expres-
sion (r = 0.154, P = 0.031) and with VEGF expression
(r = 0.161, P = 0.024) in PA, but D2R expression did not
show a correlation with VEGF expression (r = −0.025,
P = 0.725 > 0.05).
Association of D2R, MGMT and VEGF expression with
clinical features of PAs
In these 197 cases, 106 of them were male and 91 were
female; 64 of them were defined as invasive PAs, and
others were non-invasive (according to Knosp’s classifi-
cation [12]); 16 of them were recurrent PA, and the
others were primary; 16 of them were microadenomaA) and high (B) expression. (C, D): MGMT low (C) and high
Table 1 Expression profile of D2R, MGMT and VEGF in
different subtypes of PA
PA subtypes No. of
patients
D2R MGMT VEGF
Low High Low High Low High
PRL 28 2 26 24 4 11 17
GH 20 2 18 18 2 11 9
ACTH 27 9 18 22 5 13 14
TSH 15 6 9 14 1 8 7
FSH 37 6 31 26 11 8 29
NF 70 44 26 66 4 30 40
Total 197 69 128 170 27 81 116
NF, Non-functioning; Low, low expression (score of ≤3); High, high expression
(score of >3).
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(diameter > 10 mm); 159 of the PAs were tender in tumor
tissues, and the others were tenacious; Only 8 patients have
taken bromocriptine orally. The associations between clin-
ical variables and D2R, MGMT and VEGF expression are
shown in Table 2. However, there was no significant associ-
ation between D2R, MGMT or VEGF expression and clin-
ical features, including patient sex, tumor growth pattern,
tumor recurrence, tumor size, tumor tissue texture and
bromocriptine application (P > 0.05). This indicated that
despite the variety of PA clinical features, the expression of
D2R, MGMTand VEGF are definite in PAs.
Discussion
Dopamine D2 receptor is expressed in the anterior and
intermediate lobes of the pituitary gland. The responseFigure 2 The expression of D2R, MGMT and VEGF in different PAs
subtypes by detected using western blot. PRL: PRL-secreting PAs;
GH: GH-secreting PAs; ACTH: ACTH-secreting PAs; TSH: TSH-secreting
PAs; FSH: FSH-secreting PAs; NF: Non-functioning PAs. GAPDH served as
loading control. S1 = Sample 1; S2 = Sample 2.to dopamine agonists is related to the activity of the D2
receptor which belongs to the family of G protein-
coupled receptors and acts through AMP cyclase en-
zyme inhibition [13]. de Bruin et al. demonstrated that
D2 receptor expressed in more than 75% of the cell
population in normal human pituitary, indicating that
D2 receptors are not expressed only in lactotrophs and
melanotrophs, which represent no more than 30% of the
entire cell population of the normal pituitary gland [14].
In PRL secreting pituitary tumors, the high espression level
of D2 receptor explains the good therapeutic response to
dopamine agonists, which induces tumor shrinkage. In
present study, we investigated the expression of D2R in
197 cases of PAs and found that approximately 92.9% of
prolactinomas and 90% of somatotropinomas are high ex-
pression of D2R, indicating potential good drug-sensitivity
for dopamine agonists (DAs). Previous clinical studies re-
vealed that cabergoline and bromocriptine can normalize
serum PRL levels in more than 80% of prolactinomas pa-
tients [15,16] and have a good effect in somatotropinoma
patients [17], which consistent with our data from immu-
nostaining analysis. Our data also showed 83.8% of FSH-
secreting PAs and 66.7% of ACTH-secreting PAs are high
expression of D2R, which is supported by several other re-
ported studies, although clinical studies showed a long-
term cure of 48% in cabergoline treated ACTH-secreting
PAs [18-20]. Only 37.1% of non-functioning (NF) PAs
highly expressed D2R according to our data, consistenting
with the report by Colao et al. that the cumulative evidence
for NF PAs shrinkage after DA therapy is 27.6% [21].
MGMT is a DNA repair protein that counteracts the
effect of TMZ which is used for malignant glioma stand-
ard treatment. Recently, more and more studies revealed
the therapeutic effect of TMZ on PAs, especially on aggres-
sive PAs and pituitary carcinomas. MGMT expression as
assessed by immunohistochemistry may predict response
to temozolomide therapy in patients with aggressive pituit-
ary tumors [7,22]. McCormack group demonstrated that
low MGMT expression and MGMT promoter methylation
were found in the pituitary tumor of the patient who
responded to TMZ, high MGMT expression was seen in
the patient demonstrating a poor response to TMZ [23].
They reported the results that eleven out of 88 PA samples
(13%) had low MGMT expression, and that prolactinomas
were more likely to have low MGMT expression compared
with other pituitary tumor subtypes. Herein, in this study
we detected 170 out of 197 PAs (86.3%) existing MGMT
expression lower than 50% (<50%) which was considered
to be low MGMT expression. This data was higher than
that form reported clinical studies in TMZ treated func-
tioning PA, non-functioning PA and pituitary carcinoma
with the remission rate of 75%, 55% and 72% respectively,
which can be explained by Bush’s study that not all MGMT
low expression PA respond to TMZ although medical
Table 2 Association of D2R, MGMT and VEGF expression with clinicopathological characteristics from patients with PA
Parameters No. of patients D2R P MGMT P VEGF P
Low High Low High Low High
Cases 197 69 128 170 27 81 116
Gender 0.736 0.826 0.646
Male 106 36 70 92 14 42 64
Female 91 33 58 78 13 39 52
Aggressive 0.410 0.220 0.602
Yes 64 25 39 58 6 28 36
No 133 44 89 112 21 53 80
Recurrence 0.741 0.096 0.199
Yes 16 5 11 16 0 9 7
No 181 64 117 154 27 72 109
Tumor size 0.829 0.884 0.823
≤10 mm 16 6 10 14 2 7 9
>10 mm 181 63 118 156 25 74 107
Tumor texture 0.309 0.913 0.090
Tender 159 53 106 137 22 70 89
Tenacious 38 16 22 33 5 11 27
Bromocriptine 0.096 0.919 0.344
Yes 8 5 3 7 1 2 6
No 189 64 125 163 26 79 110
Low, low expression (score of ≤3); High, high expression (score of >3).
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life-threatening PAs that have failed to respond to conven-
tional treatments [24]. Our results showed low MGMT ex-
pression (<50%) in 85.7% of PRL-secreting PAs, 90% of
GH-secreting PAs, 81.5% of ACTH-secreting PAs, 93.3%
of TSH-secreting PAs, 70.3% of FSH-secreting PAs and
94.3% of non-functioning PAs, predicting almost all sub-
types of PAs are suitable for TMZ therapy, although only
fewer curative cases were separately reported [25,26]. Fur-
ther large scale clinical trials are necessary.
VEGF is a key mediator of endothelial cell prolifera-
tion, angiogenesis and vascular permeability. It plays a
pivotal role in the genesis and progression of solid tu-
mors. Onofri et al. analyzed VEGF protein expression in
39 cases of PAs, found only 5 cases (13%) were VEGF
negative [8]. Lloyd et al. examined 148 human pituitary
adenomas for VEGF protein expression by immunohis-
tochemistry, and showed positive staining in all groups
with stronger staining in GH, ACTH, TSH, and gonado-
troph adenomas and in pituitary carcinomas [27]. Our
study detected 190 positive VEGF expression cases in
197 PAs and 58.9% of them are in high expression level,
including 60.7% of PRL-secreting PAs, 78.4% FSH-
secreting PAs, 51.9% ACTH-secreting PAs and 57.1%
non-functioning PAs. Niveiro et al. investigated VEGF
expression in 60 human pituitary adenomas, and foundthat low expression of VEGF was seen predominantly in
prolactin cell adenomas, and high in non-functioning ad-
enomas, which is different from our data that 60.7% of
prolactin cell adenomas verses 57.1% non-functioning
adenomas [11]. Moreover, VEGF was considered also in-
volved in conventional medical therapy for PAs. Octreo-
tide was reported to down-regulate VEGF expression to
achieve antiangiogenic effects on PAs [28]. Gagliano et al.
demonstrated that cabergoline reduces cell viability in
non-functioning pituitary adenomas by inhibiting VEGF
secretion, of which the modulation might mediate the
effects of DA agonists on cell proliferation in non-
functioning adenoma [29]. Interestingly, in present study,
we did spearman’s rank correlation analysis and found
that D2R expression did not show a correlation with
VEGF expression. Although it is prospective to treat PAs
by anti-VEGF, up to now, only one case of PA has been
reported to be cured by bevacizumab [6]. The mecha-
nisms of VEGF in PA genesis and progression are still
unclear. More studies are needed to investigate the ef-
fects of anti-VEGF therapy on PA patients.
To confirm the results, we also detected the expres-
sion of D2R, MGMT and VEGF by using western blot.
The data supported the results of immunohistochemical
staining. Two samples were selected for each PAs sub-
type. The positive expression of western blot indicated
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thickness differences of the blot band revealed the ex-
pression level differences in separate sample.
Moreover, by spearman’s rank correlation analysis, we
found that MGMT expression was positively associated
with D2R and VEGF expression in PAs. As far as we
know, it is the first time to report the association of D2R
and MGMT expression which is positive. Only one re-
port by Moshkin et al. has ever mentioned the association
of MGMT and VEGF expression in PA. They demon-
strated a progressive regrowth and malignant transform-
ation of a silent subtype 2 pituitary corticotroph adenoma,
with significant VEGF and MGMT immunopositivity [30].
The association between VEGF and MGMT expression
in PAs need further investigations, as well as D2R and
MGMT expression.
In addition, we analyzed the association of D2R,
MGMT and VEGF expression with clinical features of
PAs, but no association was found. This indicated that
their expression was not affected by the differences of
clinical features, and that the medical therapy can be ap-
plied in any patient in need.
In conclusion, in this study we demonstrated the
expression of D2R, MGMT and VEGF in 197 different
histological subtypes of pituitary adenomas, and ana-
lyzed the relationships between D2R, MGMT and VEGF
expression and the association of D2R, MGMT and
VEGF expression with PA clinical features including pa-
tient sex, tumor growth pattern, tumor recurrence, tumor
size, tumor tissue texture and bromocriptine application.
Our data revealed that PRL-and GH-secreting PAs exist
high expression of D2R, responding to dopamine agonists;
Most PAs exist low expression of MGMT and high expres-
sion of VEGF, TMZ or bevacizumab treatment could be
applied under the premise of indications.
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